Related Experiment Videos
Lipoprotein(a) in cerebrovascular and coronary atherosclerosis
1First Department of Internal Medicine, Hiroshima University School of Medicine, Japan.
Insights
Elevated serum lipoprotein(a) [Lp(a)] levels are associated with increased severity in both cerebrovascular disease and acute myocardial infarction patients, indicating a link to atherosclerosis.
Area of Science:
- Cardiovascular Research
- Neuroscience
- Clinical Chemistry
Background:
- Serum lipoprotein(a) [Lp(a)] is a potential risk factor for cardiovascular and cerebrovascular diseases.
- Understanding Lp(a) levels in different disease states is crucial for risk stratification.
Purpose of the Study:
- To investigate the association between serum Lp(a) levels and the severity of cerebrovascular disease (CVD) and acute myocardial infarction (AMI).
- To explore the relationship between Lp(a) and atherosclerosis in cerebral and coronary arteries.
Main Methods:
- Serum Lp(a) concentrations were measured in 85 healthy controls, 49 CVD patients, and 87 AMI patients using single radial immunodiffusion.
- Non-parametric statistical methods were employed due to skewed Lp(a) distribution.
- Cerebral arteriograms and coronary angiography were used to assess lesion severity.
Main Results:
- Lp(a) levels were significantly higher in both AMI and CVD groups compared to controls.
- In CVD patients, higher Lp(a) was linked to severe lesions in major cerebral arteries, particularly in atherothrombotic infarction.
- In AMI patients, Lp(a) levels correlated positively with the number of affected coronary vessels and overall lesion severity.
Conclusions:
- High serum Lp(a) is significantly associated with increased severity of both cerebrovascular disease and acute myocardial infarction.
- Elevated Lp(a) is a marker for advanced atherosclerosis in both cerebral and coronary arteries.
- Lp(a) may play a role in the progression and severity of atherosclerotic vascular diseases.
Abstract:
Serum lipoprotein(a) [Lp(a)] was determined in 85 healthy controls (control group), in 49 patients with cerebrovascular disease (CVD group), and in 87 patients with acute myocardial infarction (AMI group). Lp(a) concentration was measured using a single radial immunodiffusion method. Because Lp(a) showed a skewed distribution, Lp(a) was plotted in each group on a box plot and analyzed using non-parametric methods. The following results were obtained: 1) Lp(a) levels were significantly higher in both the AMI and CVD groups than in the control group. 2) The CVD group was divided into 4 groups: [1] cerebral hemorrhage (HEM); [2] cardioembolic infarction (EMB); [3] lacunar infarction (LAC); and [4] atherothrombotic infarction (THR). In the THR group, Lp(a) concentration was higher than those in the control and LAC groups. 3) In the CVD group, patients with an elevated Lp(a) value showed severe lesions in the major cerebral arteries evaluated by cerebral arteriograms. 4) In the AMI patients who underwent coronary angiography, the Lp(a) level showed a marked increase with an increase in the number of affected vessels. The correlation between coronary index (CI) and Lp(a) was also investigated. The lesion severity of coronary arteries was correlated with serum Lp(a) concentration. These results suggest that a high Lp(a) value is linked to atherosclerosis of the cerebral and coronary arteries, and influences its severity.